Literature DB >> 21537357

Neuroimmunology: Assessing the value of plasma exchange in neurology.

Richard Hughes1, Hans-Peter Hartung.   

Abstract

Mesh：

Year:  2011        PMID： 21537357     DOI： 10.1038/nrneurol.2011.59

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Comparative analysis of therapeutic options used for myasthenia gravis.

Authors:  Aditya Mandawat; Henry J Kaminski; Gary Cutter; Bashar Katirji; Amer Alshekhlee
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis.

Authors:  H L Weiner; P C Dau; B O Khatri; J H Petajan; G Birnbaum; M P McQuillen; M T Fosburg; M Feldstein; E J Orav
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

Review 4.  Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Hans-Peter Hartung
Journal:  J Neuroimmunol       Date:  2010-11-05       Impact factor: 3.478

Review 5.  Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  I Cortese; V Chaudhry; Y T So; F Cantor; D R Cornblath; A Rae-Grant
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

6.  Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

Authors:  A F Hahn; C F Bolton; N Pillay; C Chalk; T Benstead; V Bril; K Shumak; M K Vandervoort; T E Feasby
Journal:  Brain       Date:  1996-08       Impact factor: 13.501

7.  Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors: 
Journal:  Neurology       Date:  1996-09       Impact factor: 9.910

8.  Remission of myasthenia gravis following plasma-exchange.

Authors:  A J Pinching; D K Peters
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

Review 9.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 10.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002
  10 in total
  1 in total

1.  Plasmapheresis: are bigger studies necessarily better?

Authors:  Brian Weinshenker
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.